ABSTRACT
OBJECTIVE: To describe the epidemiological, clinical, microbiological, and therapeutic features and outcomes of Rothia infective endocarditis (RIE) and extracardiac infections (ECRI). METHODS: We performed a systematic literature review of published cases of RIE and ECRI. RESULTS: After inclusion of a personal case report, 51 cases of RIE and 215 cases of ECRI were reported. Compared with ECRI patients, RIE patients were significantly more often males (80% versus 59%), intravenous drug users (IVDU) (20% versus 3%), immunocompetent (76% versus 31%), and infected with R. dentocariosa (55% versus 13%) but lacked significant differences with regard to median age (45 years [6-79]), rate of orodental abnormalities (33%), and six-month mortality (14%). Following microbiological documentation, RIE was most often treated with a beta-lactam antibiotic alone (39%) for a median duration of six weeks and required surgery in 39% of cases. CONCLUSION: RIE is rare and likely secondary to a dental portal of entry or cutaneous inoculation in IVDU. Its prognosis seems to be favorable.
Subject(s)
Endocarditis, Bacterial/epidemiology , Endocarditis, Bacterial/microbiology , Micrococcaceae/pathogenicity , Adolescent , Adult , Aged , Anti-Bacterial Agents/therapeutic use , Cardiac Surgical Procedures/methods , Child , Echocardiography/methods , Endocarditis/epidemiology , Endocarditis/microbiology , Endocarditis/therapy , Endocarditis, Bacterial/therapy , Female , Humans , Male , Micrococcaceae/isolation & purification , Middle Aged , Treatment Outcome , Young Adult , beta-Lactams/therapeutic useABSTRACT
The subcutaneous route is a widely used route of administration in routine clinical practice, particularly in elderly patients, when the intravenous route cannot be used. This review of the literature highlights the lack of randomized studies and the lack of pharmacokinetic data on the use of this route of administration. Three antibiotics administered subcutaneously can be used for severe infections, with acceptable pharmacokinetic and pharmacodynamic data, when the intravenous administration is not possible: ceftriaxone, ertapenem, and teicoplanin.
Subject(s)
Anti-Bacterial Agents/administration & dosage , Bacterial Infections/drug therapy , Injections, Subcutaneous , Age Factors , Anti-Bacterial Agents/blood , Anti-Bacterial Agents/pharmacokinetics , Bacterial Infections/blood , Ceftriaxone/administration & dosage , Ceftriaxone/pharmacokinetics , Clinical Trials as Topic , Cohort Studies , Ertapenem/administration & dosage , Ertapenem/pharmacokinetics , Humans , Infusions, Intravenous , Injections, Intravenous , Microbial Sensitivity Tests , Teicoplanin/administration & dosage , Teicoplanin/pharmacokineticsABSTRACT
OBJECTIVES: To provide up-to-date guidelines on management of pelvic inflammatory disease (PID). METHODS: An initial search of the Cochrane database, PubMed, and Embase was performed using keywords related to PID to identify reports in any language published between January 1990 and January 2012, with an update in 2018. All identified reports published in French and English relevant to the areas of focus were included. A level of evidence based on the quality of the data available was applied for each area of focus and used for the guidelines. RESULTS: PID must be suspected when spontaneous pelvic pain is associated with induced adnexal or uterine pain (grade B). Pelvic ultrasonography is necessary to exclude tubo-ovarian abscess (TOA) (grade C). Microbiological diagnosis requires endocervical and TOA sampling for molecular and bacteriological analysis (grade B). First-line treatment for uncomplicated PID combines ceftriaxone 1g, once, by intra-muscular (IM) or intra-venous (IV) route, doxycycline 100mg×2/d, and metronidazole 500mg×2/d oral (PO) for 10 days (grade A). First-line treatment for complicated PID combines IV ceftriaxone 1 to 2g/d until clinical improvement, doxycycline 100mg×2/d, IV or PO, and metronidazole 500mg×3/d, IV or PO for 14days (grade B). Drainage of TOA is indicated if the collection measures more than 3cm (grade B). Follow-up is required in women with sexually transmitted infections (STI) (grade C). The use of condoms is recommended (grade B). Vaginal sampling for microbiological diagnosis is recommended 3 to 6months after PID (grade C), before the insertion of an intra-uterine device (grade B), before elective termination of pregnancy or hysterosalpingography. Targeted antibiotics on identified bacteria are better than systematic antibioprophylaxis in those conditions. CONCLUSIONS: Current management of PID requires easily reproducible investigations and antibiotics adapted to STI and vaginal microbiota.
Subject(s)
Pelvic Inflammatory Disease , Anti-Bacterial Agents/administration & dosage , Female , Humans , Infections/drug therapy , Infections/microbiology , Intrauterine Devices , Pelvic Inflammatory Disease/diagnosis , Pelvic Inflammatory Disease/microbiology , Pelvic Inflammatory Disease/therapy , Pelvic Pain , Sexually Transmitted Diseases , UltrasonographyABSTRACT
A tubo-ovarian abscess (ATO) should be suspected in a context of pelvic inflammatory disease (PID) in case of severe pain associated with the presence of general signs and palpation of an adnexal mass at pelvic examination. Imaging allows most often a rapid diagnosis, by ultrasound or CT, the latter being irradiant but also allowing to consider the differential diagnoses (digestive or urinary diseases) in case of pelvic pain. MRI, non-irradiating examination, whenever it is feasible, provides relevant information, more efficient, guiding quickly the diagnosis. The diagnosis of tubo-ovarian abscess should lead to the hospitalization of the patient, the collection of bacteriological samples, the initiation of a probabilistic antibiotherapy associated with drainage of the purulent collection. In severe septic forms (generalized peritonitis, septic shock), surgery (laparoscopy or laparotomy) keeps its place. In other situations, ultrasound-guided trans-vaginal puncture in the absence of major hemostasis disorders or severe sepsis is a less morbid alternative to surgery and provides high rates of cure. Today, ultrasound-guided trans-vaginal puncture has been satisfactory evaluated in the literature and is part of a logic of therapeutic de-escalation. Randomized trials evaluating laparoscopic drainage versus radiological drainage should be able to answer, in the coming years, questions that are still outstanding (impact on chronic pelvic pain, fertility). The recommendations for the management of ATO published in 2012 by the CNGOF remain valid, legitimizing the place of radiological drainage associated with antibiotic therapy.
Subject(s)
Abscess/diagnosis , Abscess/therapy , Fallopian Tube Diseases/therapy , Ovarian Diseases/therapy , Pelvic Inflammatory Disease/therapy , Anti-Bacterial Agents/therapeutic use , Drainage/methods , Fallopian Tube Diseases/microbiology , Female , Humans , Ovarian Diseases/microbiology , Pelvic Inflammatory Disease/drug therapy , Pelvic Inflammatory Disease/microbiologyABSTRACT
This review of the treatment of uncomplicated pelvic inflammatory disease (PID) focuses on the susceptibility profile of the main microbiological causes as well as on the advantages and inconvenients of relevant antibiotics. As bacterial resistance is expanding in the community, the rules of adequate antibiotic prescribing are integrated in the treatment proposals. While the pathogenic role of anaerobic bacteria in uncomplicated PID remains discussed, the choice to provide anaerobes coverage is proposed. Thus, the antibiotic treatment has to cover Chamydia trachomatis, Neisseria gonorrhoeae, anaerobes as well as Streptococcus spp, gram negative bacteria and the ermerging Mycoplasma genitalium. On the basis of published trials and good practice antibiotic usage, the ceftriaxone-doxycycline-metronidazole combination has been selected as the first line regimen. Fluoroquinolones (moxifloxacin alone, or levofloxacin or ofloxacin combined with metronidazole) are proposed as alternatives because of their ecological impact and their side effects leading to restricted usage. When fluoroquinolone are used, ceftriaxone should be added in case of possible sexually transmitted infection. When detected, M. genitalium should be treated by moxifloxacin. Moreover, this review highlights the need to better describe the microbiological epidemiology of uncomplicated PID in France or Europe.
Subject(s)
Pelvic Inflammatory Disease/drug therapy , Pelvic Inflammatory Disease/microbiology , Anti-Bacterial Agents/therapeutic use , Bacterial Infections/drug therapy , Chlamydia Infections/drug therapy , Chlamydia trachomatis , Drug Resistance, Bacterial , Female , France , Gonorrhea/drug therapy , Humans , Mycoplasma Infections/drug therapy , Mycoplasma genitalium , Sexually Transmitted Diseases/drug therapy , Sexually Transmitted Diseases/microbiology , Streptococcal Infections/drug therapySubject(s)
Anemia, Hemolytic/chemically induced , Anemia, Hemolytic/diagnosis , Artemether, Lumefantrine Drug Combination/adverse effects , Adult , Anemia, Hemolytic/pathology , Delayed Diagnosis , Diagnosis, Differential , Female , Humans , Late Onset Disorders/chemically induced , Late Onset Disorders/diagnosisABSTRACT
BACKGROUND: Despite the development of new microbiologic technologies, blood cultures (BCs) remain the first-line tool for the diagnosis of bloodstream infections. Their diagnostic value may be affected when a microorganism of questionable evidence is isolated-for example, coagulase-negative staphylococci, Bacillus spp., viridans group streptococci, Corynebacterium spp., Propionibacterium spp. and Micrococcus spp. Finally, making a correct diagnosis of pathogenicity (vs. contamination) is challenging. AIMS: To review the current ways of dealing with the problem of BC contaminants (BCCs) and to provide practical suggestions to decrease BCC rates. SOURCES: PubMed electronic databases and existing reviews were searched up to December 2017 to retrieve relevant publications related to the topic. CONTENTS: This review describes the burden of BCC and analyses the main current issues and controversies in interpreting the occurrence of potential BC contaminants. It focuses on the best-described approaches to decide whether BCC is present and discusses the different strategies of prevention in adults. IMPLICATIONS: Each institution should have an efficient policy to prevent BCC, emphasizing the importance of following guidelines for prescribing and collecting BCs. Training healthcare workers should focus on detrimental influence on patient care and highlight the work and costs due to contaminants. The accurate differentiation of a contaminant from a true pathogen relies on a multidisciplinary approach and the clinical judgement of experienced practitioners.
Subject(s)
Bacteriological Techniques/standards , Blood Culture/standards , Clinical Laboratory Services/standards , Health Personnel/education , HumansABSTRACT
The ability to kill individual or groups of cells in vivo is important for studying cellular processes and their physiological function. Cell-specific genetically encoded photosensitizing proteins, such as KillerRed, permit spatiotemporal optogenetic ablation with low-power laser light. We report dramatically improved resolution and speed of cell targeting in the zebrafish kidney through the use of a selective plane illumination microscope (SPIM). Furthermore, through the novel incorporation of a Bessel beam into the SPIM imaging arm, we were able to improve on targeting speed and precision. The low diffraction of the Bessel beam coupled with the ability to tightly focus it through a high NA lens allowed precise, rapid targeting of subsets of cells at anatomical depth in live, developing zebrafish kidneys. We demonstrate that these specific targeting strategies significantly increase the speed of optoablation as well as fish survival.
Subject(s)
Optogenetics/methods , Zebrafish/metabolism , Animals , Fluorescence , Green Fluorescent Proteins/metabolism , Time FactorsABSTRACT
PURPOSE: We determined the prevalence of ESBL Enterobacteriaceae in urinary tract infections among inpatients, identified risk factors of acquisition, and evaluated the effectiveness of alternatives to carbapenems. METHODS: The clinical, microbiological, and therapeutic data as well as the outcomes were recorded for all ESBL-E positive urine samples for three months. RESULTS: Thirty-one (4%) of the 762 Enterobacteriaceae positive cultures were ESBL producers. The predisposing conditions for being infected with those strains were: immunodepression (61%), recent hospitalization (52%), recent antibiotic therapy (52%), and urinary catheterization (61%). 19% of infections were community acquired. The seven cases of acute pyelonephritis and five of prostatitis were treated with piperacillin-tazobactam (5), fluoroquinolones (4), ceftazidime (2), or carbapenems (only 1) after specialized advice. Four (33%) patients relapsed at week 10: three were immunodepressed and three presented with bacteremia. CONCLUSIONS: Alternatives to carbapenems (especially piperacillin-tazobactam) seem to be a good option for non-bacteremic UTI in immunocompetent patients.
Subject(s)
Anti-Bacterial Agents/therapeutic use , Bacterial Proteins/physiology , Enterobacteriaceae Infections/drug therapy , Enterobacteriaceae/enzymology , Urinary Tract Infections/drug therapy , beta-Lactam Resistance , beta-Lactamases/physiology , Adult , Aged , Anti-Bacterial Agents/classification , Catheter-Related Infections/drug therapy , Catheter-Related Infections/microbiology , Ceftazidime/therapeutic use , Community-Acquired Infections/drug therapy , Community-Acquired Infections/microbiology , Cross Infection/drug therapy , Cross Infection/microbiology , Enterobacteriaceae/drug effects , Enterobacteriaceae Infections/microbiology , Female , Fluoroquinolones/therapeutic use , Hospitalization , Hospitals, University , Humans , Immunocompromised Host , Male , Middle Aged , Penicillanic Acid/analogs & derivatives , Penicillanic Acid/therapeutic use , Piperacillin/therapeutic use , Piperacillin, Tazobactam Drug Combination , Prevalence , Prostatitis/drug therapy , Prostatitis/microbiology , Recurrence , Retrospective Studies , Risk Factors , Urinary Tract Infections/microbiology , Young AdultABSTRACT
Detection of microorganisms by blood cultures (BCs) is essential in managing patients with bacteraemia. Rather than the number of punctures, the volume of blood drawn is considered paramount in efficient and reliable detection of microorganisms. We performed a 1-year prospective multicentre study in adult emergency departments of three French university hospitals comparing two methods for BCs: a unique blood culture (UBC) collecting a large volume of blood (40 mL) and the standard method of multiple blood cultures (MBC). The performances of both methods for bacterial contamination and efficient microbial detection were compared, each patient serving as his own control. Amongst the 2314 patients included, three hundred were positive for pathogens (n=245) or contaminants (n=55). Out of the 245 patients, 11 were positive for pathogens by UBC but negative by MBC and seven negative by UBC but positive by MBC (p 0.480). In the subgroup of 137 patients with only two BCs, UBC was superior to MBC (p 0.044). Seven and 17 patients had contaminated BCs by UBC and MBC only, respectively (p 0.062). Considering the sums of pathogens missed and contaminants, UBC significantly outperformed MBC (p 0.045). Considering the complete picture of cost savings, efficient detection of microorganisms and decrease in contaminations, UBC offers an interesting alternative to MBC.
Subject(s)
Bacteremia/diagnosis , Bacteriological Techniques/methods , Blood/microbiology , Emergency Medicine/methods , Specimen Handling/methods , Adolescent , Adult , Aged , Aged, 80 and over , Emergency Service, Hospital , Female , France , Hospitals, University , Humans , Male , Middle Aged , Prospective Studies , Young AdultABSTRACT
Campylobacter has been associated with immunoproliferative small intestinal disease (IPSID), on the basis of 16S rDNA sequencing, in situ hybridization, and immunohistochemistry. Here, for the first time, we have cultured Campylobacter from the stools of a patient with IPSID. Phenotypic analysis and whole genome sequencing identified Campylobacter coli. PCR on a IPSID tissue biopsy sample was positive for Campylobacter coli and negative for Campylobacter jejuni. These findings further support a causative role for Campylobacter in the development of IPSID.
Subject(s)
Campylobacter coli/isolation & purification , Feces/microbiology , Immunoproliferative Small Intestinal Disease/microbiology , Sequence Analysis, DNA , Adult , Campylobacter coli/genetics , DNA, Bacterial/chemistry , DNA, Bacterial/genetics , Genome, Bacterial , Histocytochemistry , Humans , Immunohistochemistry , Immunoproliferative Small Intestinal Disease/pathology , Male , Microscopy , Positron-Emission Tomography , Radiography, AbdominalSubject(s)
Community-Acquired Infections/microbiology , Endocarditis, Bacterial/microbiology , Methicillin-Resistant Staphylococcus aureus/isolation & purification , Staphylococcal Infections/microbiology , Adult , Anti-Bacterial Agents/therapeutic use , Bacterial Typing Techniques , Communicable Diseases, Emerging/microbiology , Community-Acquired Infections/diagnosis , Community-Acquired Infections/drug therapy , Community-Acquired Infections/epidemiology , Endocarditis, Bacterial/diagnosis , Endocarditis, Bacterial/drug therapy , Endocarditis, Bacterial/epidemiology , Female , Gastrectomy , Genes, Bacterial , Gentamicins/therapeutic use , Humans , Lymphoma, B-Cell, Marginal Zone/radiotherapy , Lymphoma, B-Cell, Marginal Zone/surgery , Methicillin-Resistant Staphylococcus aureus/classification , Methicillin-Resistant Staphylococcus aureus/genetics , Mitral Valve Insufficiency/complications , Multiple Sclerosis/complications , Neoplasms, Second Primary/diagnosis , Ovarian Neoplasms/complications , Ovarian Neoplasms/diagnosis , Postoperative Complications/diagnosis , Postoperative Complications/drug therapy , Postoperative Complications/epidemiology , Postoperative Complications/microbiology , Rifampin/therapeutic use , Staphylococcal Infections/diagnosis , Staphylococcal Infections/drug therapy , Staphylococcal Infections/epidemiology , Stomach Neoplasms/radiotherapy , Stomach Neoplasms/surgery , Vancomycin/therapeutic useABSTRACT
Pelvic inflammatory disease (PID) is caused by a large spectrum of micro-organisms. However, the microbiological cause is unknown in approximately half of cases according to varying series. In the context of sexually transmitted disease (STD), the most frequently identified microorganisms causing PID are Neisseria gonorrhoeae, Chlamydia trachomatis and Mycoplasma genitalium. In such cases, bacterial vaginosis and Trichomonas vaginalis are frequently associated. In case of complicated PID or when PID is the consequence of delivery, abortion, intra-uterine procedure, bacteria that come from vaginal carriage may be encountered: Enterobacteriacae, Staphylococcus spp., Streptococcus spp., anaerobes. Mycopslama hominis as well as Ureaplasma urealyticum may also be found in this context. The microbiological diagnosis may be performed on samples of vaginal liquid, endocervix or, when available, surgical specimens. The microbiological diagnostic procedures that are used to identify these microrgansims are reviewed. Vaginal sampling may help to identify N. gonorrhoeae, C. trachomatis and M. genitalium using nucleic acid amplification tests (NAAT), and is also of interest because of the epidemiological association of PID to bacterial vaginosis and trichomoniasis. Samples from the endocervix, and if available, from endometrial biopsy surgical procedures, should be processed to detect N. gonorrhoeae, C. trachomatis and M. genitalium using NAAT, and to search for the presence of Neisseria gonorrhoeae (antibiogram should be performed), facultative anaerobes, anaerobes and capnophilic bacteria. The antibiotic treatment should at least cover N. gonorrhoeae, C. trachomatis and M. genitalium, and for most of the authors, anaerobes. In case, microbiological studies demonstrate the role of other bacteria (e.g., Enterobacteriacae), theses should be treated according to the results of antibiogram.
Subject(s)
Pelvic Inflammatory Disease/microbiology , Pelvic Inflammatory Disease/therapy , Anti-Bacterial Agents/therapeutic use , Chlamydia trachomatis/isolation & purification , Female , Humans , Mycoplasma genitalium/isolation & purification , Neisseria gonorrhoeae/isolation & purification , Pelvic Inflammatory Disease/diagnosis , Sexually Transmitted Diseases/complications , Sexually Transmitted Diseases/microbiology , Vaginosis, Bacterial/complicationsABSTRACT
The antibiotic treatment is indispensable for the treatment of the tubo-ovarian abscesses (TOA). It has to have a wide spectre and would be secondarily adapted in case of a sexually transmitted infection. The surgery remains indicated in first intention in case of vital threat (generalized peritonitis, toxic shock). In the not complicated TOA, the evacuation of abscesses (by draining under imaging or laparoscopy) with the antibiotic treatment gives better rates of cure than the antibiotic treatment alone. For the surgery, several entrys are possible. The laparoscopy allows a shorter hospitalization with fewer complications and a faster resolution of the fever than the laparotomy. The conservative surgery, realized by laparoscopy, has hight rates of successes with few complications. The radical surgery, by coelioscopy or by laparotomy, has high rates of complications. Transvaginal ultrasound guided aspiration is an alternative in the drainage by laparscopy with identical succes. It has been well evaluated. It has low morbidity and can be proposed in first intention in not complicated TOA.
Subject(s)
Abscess/drug therapy , Abscess/surgery , Fallopian Tube Diseases/drug therapy , Fallopian Tube Diseases/surgery , Ovarian Diseases/drug therapy , Ovarian Diseases/surgery , Abscess/microbiology , Anti-Bacterial Agents/therapeutic use , Combined Modality Therapy , Drainage , Fallopian Tube Diseases/microbiology , Female , Humans , Laparoscopy , Ovarian Diseases/microbiology , Peritonitis/etiology , Peritonitis/surgery , Shock, Septic/etiology , Shock, Septic/surgery , Suction , VaginaABSTRACT
Microsporidiosis is an opportunistic infection in organ transplant recipients and patients with other cellular immunodeficiency. Fumagillin is an effective treatment against Enterocytozoon bieneusi, one of the two main species causing the microsporidiosis involved in human diseases. We report the first case, to our knowledge, of a probable drug-induced aseptic meningoencephalitis, after administration of fumagillin in a kidney transplant recipient with microsporidiosis.
Subject(s)
Antifungal Agents/adverse effects , Cyclohexanes/adverse effects , Fatty Acids, Unsaturated/adverse effects , Kidney Transplantation/adverse effects , Meningoencephalitis/etiology , Microsporidiosis/drug therapy , Cyclohexanes/therapeutic use , Fatty Acids, Unsaturated/therapeutic use , Female , Humans , Immunocompromised Host , Middle Aged , Sesquiterpenes/adverse effects , Sesquiterpenes/therapeutic useABSTRACT
PURPOSE: To determine the association of clinical outcomes with the adherence to Infectious Diseases Consultation (IDC) recommendations. METHODS: From March to August 2009, all patients hospitalized in our hospital, for whom an IDC was requested, were prospectively enrolled. The adherence to recommendations was ascertained after 72 h from the IDC. The primary objective of the study was to evaluate the clinical cure rate 1 month after the IDC, according to the adherence to IDC recommendations. RESULTS: An IDC was requested for 258 inpatients. The infectious disease (ID) was most often non-severe (66%), community-acquired (62%), and already under treatment (47%). IDC proposals were most often formulated via a formal consultation (57%). Physicians' adherence to IDC recommendations was 87% for diagnostic tests and 90% for antibiotherapy. In the multivariate analysis, severe infections and direct consultation were independently associated with increased odds of adherence to recommendations for performing diagnostic tests (odds ratios 5.4 and 4.0, respectively). The overall clinical cure rate was 84% and this did not differ according to the adherence to IDC recommendations for diagnostic tests (84.3 vs. 71.4%, p = 0.15) and antimicrobial treatment (84.8 vs. 77.8%, p = 0.34). CONCLUSIONS: Some limitations of the study may explain the lack of evidence of a clinical benefit, such as the very high level of adherence to IDC recommendations and the low proportion of severe infections. However, clinical improvement was always better when recommendations were followed. Therefore, further larger randomized multicentric studies including more patients suffering from more severe IDs may be needed in order to demonstrate a clinical impact.